NCT05202795 is a clinical trial in Postpartum Pain, sponsored by Northwestern University.

Who is sponsoring NCT05202795?

NCT05202795 is sponsored by Northwestern University.

What condition does NCT05202795 study?

NCT05202795 studies Postpartum Pain, Pain Management, Opioid Prescribing.

Is NCT05202795 still recruiting?

NCT05202795 is currently completed. Last updated 8 February 2023.

Last reviewed 2023-02-08 · How we verify

NCT05202795

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Postpartum Pain Experience and Attitudes About Opioid Prescribing

Completed Last updated 8 February 2023

What this trial tests

trial in Postpartum Pain in 46 participants. Completed in 1 July 2022.

Timeline

1 January 2022

Primary endpoint
1 July 2022

1 July 2022

Quick facts

Lead sponsor	Northwestern University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	46
Start date	1 January 2022
Primary completion	1 July 2022
Estimated completion	1 July 2022
Sites	1 location across United States

Conditions studied

Postpartum Pain — all drugs for Postpartum Pain →
Pain Management — all drugs for Pain Management →
Opioid Prescribing — all drugs for Opioid Prescribing →

Sponsor

Northwestern University

Who can join

18 and older, any sex, with Postpartum Pain or Pain Management. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective qualitative study of obstetric clinicians examining factors which influence their approach to postpartum pain management, their perspectives and preferences of interventions aimed at reducing opioid use, and the biases which may contribute disparities in this setting.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Northwestern University trials

Trials by the same sponsor.

NCT06545695 — Epidermal Growth Factor Receptor Inhibition for Keratinopathies · Phase 1, PHASE2 · not yet recruiting
NCT07261657 — N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive C · EARLY_PHASE1 · not yet recruiting
NCT07392775 — ALDH2 Genetic Testing in East Asian Community · NA · not yet recruiting
NCT06886776 — Implementing A Secure Firearm Storage Program in Illinois Health Centers in Partnership With AllianceChicago and the Ill · NA · not yet recruiting
NCT07469176 — Co-Designing and Evaluating Additional Mothers and Babies Program Content for Expectant and New Parents of Children With · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05202795 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Northwestern University
Last refreshed: 8 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05202795.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing